Cannabis for Brain Tumor Patients: Symptom Relief and Possible Anti-Tumor Effects
Cannabinoids show established benefit for palliative symptoms in brain tumor patients and remarkable tumor regression (50-95%) in animal glioma studies, with combination approaches showing synergistic effects.
Quick Facts
What This Study Found
This review examined the dual role of cannabinoids in brain tumor care: established palliative symptom management and emerging anti-tumor potential.
For palliative care, cannabinoids have documented roles in managing nausea, vomiting, pain, anxiety, and sleep disturbances in cancer patients. THC and nabilone also address anorexia and weight loss, while CBD has no appetite-stimulating effect but offers anxiolytic and antidepressant properties without psychoactive effects. Low-dose THC can improve mood.
The anti-tumor findings from animal glioma studies were striking. Relatively high doses of CBD and THC demonstrated significant tumor regression ranging from approximately 50% to 95%, with rare cases of complete tumor eradication. Adding radiation therapy (X-rays) or chemotherapy (temozolomide) enhanced the anti-tumor activity further. THC combined with CBD showed synergistic effects beyond either compound alone.
The authors concluded that while many questions remain about optimal treatment schedules, current evidence suggests cannabinoids could play an important role in brain tumor patient care.
Key Numbers
Animal glioma studies showed 50-95% tumor volume regression with CBD and THC at high doses. Combination with temozolomide or radiation enhanced effects. THC+CBD showed synergistic anti-tumor activity.
How They Did This
Narrative review of currently available cannabinoid preparations (dronabinol, CBD, nabiximols, nabilone), their palliative applications in brain tumor patients, and preclinical glioma studies examining anti-tumor effects.
Why This Research Matters
Brain tumors, particularly gliomas, have among the worst prognoses of any cancer. Any treatment that could both improve quality of life through symptom management and potentially slow tumor growth represents a significant clinical opportunity.
The Bigger Picture
The convergence of palliative benefit and anti-tumor potential makes cannabinoids uniquely positioned in oncology. Most palliative treatments are symptom-focused only, while most anti-tumor treatments worsen quality of life. Cannabinoids potentially do both simultaneously.
What This Study Doesn't Tell Us
The impressive anti-tumor results are from animal studies with high cannabinoid doses that may not translate directly to human tumors. No large human clinical trials of cannabinoids as anti-tumor agents for brain tumors had been completed. Optimal dosing and treatment schedules for humans are unknown.
Questions This Raises
- ?Can the animal tumor regression results be replicated in human glioblastoma trials?
- ?What is the optimal THC:CBD ratio for anti-tumor effects?
- ?Would cannabinoids work as adjuncts to standard glioma treatment or only as alternatives?
Trust & Context
- Key Stat:
- Animal glioma studies showed 50-95% tumor regression with cannabinoids
- Evidence Grade:
- Narrative review with strong palliative evidence and compelling but preclinical anti-tumor data. Moderate overall because the anti-tumor findings await human confirmation.
- Study Age:
- Published in 2017.
- Original Title:
- The use of cannabis in supportive care and treatment of brain tumor.
- Published In:
- Neuro-oncology practice, 4(3), 151-160 (2017)
- Authors:
- Likar, Rudolf(2), Nahler, Gerhard(2)
- Database ID:
- RTHC-01437
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can cannabis shrink brain tumors?
Animal studies showed CBD and THC produced 50-95% tumor regression in glioma models, with some cases of complete eradication. However, these are animal results using high doses, and human clinical trials are needed to confirm whether similar effects occur in people.
How do cannabinoids help brain tumor patients?
Established benefits include relief from nausea, vomiting, pain, anxiety, sleep problems, and appetite loss. THC can improve mood at low doses, while CBD offers anxiety and depression relief without psychoactive effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01437APA
Likar, Rudolf; Nahler, Gerhard. (2017). The use of cannabis in supportive care and treatment of brain tumor.. Neuro-oncology practice, 4(3), 151-160. https://doi.org/10.1093/nop/npw027
MLA
Likar, Rudolf, et al. "The use of cannabis in supportive care and treatment of brain tumor.." Neuro-oncology practice, 2017. https://doi.org/10.1093/nop/npw027
RethinkTHC
RethinkTHC Research Database. "The use of cannabis in supportive care and treatment of brai..." RTHC-01437. Retrieved from https://rethinkthc.com/research/likar-2017-the-use-of-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.